Vaccines
Vaccines aim to activate a specific immune response and various peptide/protein vaccines are currently under investigation for tumor treatment. Examples include peptides derived from myeloma-associated antigens, such as mutant Wilms tumor 1 (WT 1), X-box binding protein 1 (XBP1), syndecan-1 (CD138), and CS1 (CD319).
Filter by content:
Types
- MGUS
- Newly diagnosed multiple myeloma
- Relapsed/refractory multiple myeloma
- Smoldering multiple myeloma
Therapeutics
- Auto-HSCT
- Carfilzomib
- Dexamethasone
- Elotuzumab
- Lenalidomide
- Melphalan
- PVX-410 Vaccines
Congresses
- ASCO 2019
- ASH 2017
- ASH 2019
- COMy 2019
- ESH 2018
Trials
- GEM-CESAR
Expert Opinions
- Francesca Gay
- Irene Ghobrial
- María-Victoria Mateos
- Sagar Lonial
Educational Resources
Notable Articles
- Smoldering multiple myeloma (SMM): an introduction to this month’s educational theme on the multiple myeloma (MM) Hub
Starting July 2019, the Multiple Myeloma (MM) Hub will be featuring articles centered around an... - David Avignan | ESH MM 2018 | Vaccines in myeloma
David Avignan comments on the challenges of creating specific, yet broad-targeting, vaccines as... - PVX-410 vaccine alone or with lenalidomide for patients with smoldering multiple myeloma
PVX-410 is safe and can increase immunogenicity in a patient population with smoldering myeloma...